Drug Profile
Petesicatib - Roche
Alternative Names: RG 7625; RO 5459072Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Class Cyclopropanes; Pyrrolidines; Small molecules
- Mechanism of Action Cathepsin S inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Coeliac disease; Psoriasis; Sjogren's syndrome
Most Recent Events
- 25 Jun 2020 Roche completes a phase-II trial in Psoriasis (In adults, In the elderly) in Germany (PO) (EudraCT2018-002446-36)
- 16 Oct 2019 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in Netherlands (PO) (Roche pipeline, October 2019)
- 16 Oct 2019 Discontinued - Phase-I for Coeliac disease in United Kingdom (PO) (Roche pipeline, October 2019)